TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Vital KSK Holdings, Inc. ( (JP:3151) ) has shared an update.
Vital KSK Holdings, Inc. has announced the establishment of a new subsidiary to further its pharmaceutical business operations, specifically to handle the development and commercialization of ACCRUFeR®, an iron deficiency treatment. This strategic move, following an exclusive license agreement with Shield Therapeutics, aims to strengthen the company’s position in the Japanese pharmaceutical market. The subsidiary will be fully owned by Vital KSK Holdings, with key personnel from the parent company taking leadership roles. The financial impact of this establishment is expected to be minimal for the fiscal year ending March 2026.
The most recent analyst rating on (JP:3151) stock is a Buy with a Yen1387.00 price target. To see the full list of analyst forecasts on Vital KSK Holdings, Inc. stock, see the JP:3151 Stock Forecast page.
More about Vital KSK Holdings, Inc.
Vital KSK Holdings, Inc. operates in the pharmaceutical industry, focusing on the research, development, manufacturing, and sales of pharmaceuticals. The company is expanding its market focus in Japan through its wholly-owned subsidiary, VITAL-NET, Inc., which has secured exclusive rights to develop and market Shield Therapeutics Plc’s iron deficiency treatment, ACCRUFeR®.
Average Trading Volume: 102,255
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen56.24B
For a thorough assessment of 3151 stock, go to TipRanks’ Stock Analysis page.